Generic versions of Bristol Myers Squibb’s top-selling cancer drug Revlimid (lenalidomide) have been launched across Europe today, with Sandoz and Stada among the leading generics firms to have confirmed the introduction of their versions in numerous European markets.
Accord had also previously indicated plans to launch generic lenalidomide from 18 February in Europe, under the terms of a settlement with the originator, having been among